ENLV Covid-19 Treatment. It works.
ENLV Covid-19 Treatment ?? ?? ??
First-time DD post here. The play in Enlivex, or ENLV. Owned by ARK and Cathie has been adding heavy lately. As of February 10, 2021, Ark has 373k shares of ENLV, after adding 37k on Wednesday. ?? ?? ??
ELVN is a biotech company that is developing a drug for sepsis, Allocetra. Allocetra is a drug meant to treat the overreaction of the immune system. So the geniuses at Enlivex thought, hey, maybe this will work for covid-19, by preventing the body from over-reacting and cytokine storm from happening, thus stopping the worst of covid-19. The treatment infuses billions of early apoptotic cells, or dying cells, into the bloodstream. Macrophages and dendritic cells, the body’s first responders, feed on these apoptotic cells, releasing fewer cytokine alert signals and calming the storm. The study drug, Allocetra-OTS, is based on the known activity of apoptotic cells to contribute to maintenance of peripheral immune homeostasis. An altered immune response is associated with organ dysfunction in sepsis, so the possibility is being tested that the study drug can improve the condition of sepsis. Sepsis is a big deal. But first see what it did for covid-19 in Phase Ib and Phase II trials.
Phase II + Ib (21 patients treated)
11/21 (52%) with severe illness10/21 (48%) with critical illness0/21 (0%) mortality on day-28 19/21 (90.5%) patients recovered and were discharged from the hospital by day-28 Average duration of hospitalization post administration of AllocetraTM for discharged patients was 5.6 days 2/21 (9.5%) patients, both of whom had critical illness at the time of AllocetraTM treatment, were hospitalized in the ICU on a respirator on day-28
100% survival rate for severe and critical patients
[https://www.globenewswire.com/news-release/2020/12/03/2139086/0/en/Enlivex-Reports-Positive-Interim-Results-From-Phase-II-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients.html](https://www.globenewswire.com/news-release/2020/12/03/2139086/0/en/Enlivex-Reports-Positive-Interim-Results-From-Phase-II-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients.html)
Check out their January 2021 investor presentation here: [https://enlivex.com/wp-content/uploads/2021/01/enlivex-investor-presentation-jan-2021.pdf ](https://enlivex.com/wp-content/uploads/2021/01/enlivex-investor-presentation-jan-2021.pdf)
The investor presentation shows the covid-19 related market size as $1 billion, but the real kicker is if it gets approved for sepsis, because that is a $30 billion market. The sepsis market is 30x that of the covid-19 market. Allocetra has also shown efficacy for sepsis.And $ENLV market cap is only $332 million. Way undervalued with the potential and positive results for Allocetra.
Here is some data from the Phase I trials for sepsis:
The Acute Physiology and Chronic Health Evaluation (APACHEII) score of the AllocetraTM-treated group was 12.9, and the corresponding probability of mortality of at least one patient in that group was predicted at 85% based on the hospital ICU staff’s clinical assessment of that patient’s overall condition at admission. However, none (0%) of the AllocetraTM-treated patients died during the 28-day study period, as compared to 27% mortality in the matched control group during the same 28-day period. Each of the 10 AllocetraTM-treated patients had between 2 to 5 dysfunctional organ systems upon admission to the ICU. All (100%) of the AllocetraTM-treated patients had rapid and complete recovery from their septic conditions and any organ dysfunction that was present upon admission to the ICU. Despite the similar SOFA score at admission between the AllocetraTM-treated patients and the matched controls (average of 3.4 versus 3.47), no AllocetraTM-treated patients had an increase in organ-failure state post AllocetraTM treatment, while the majority of matched controls had an increase in organ-failure state. The average worsening in organ-failure state of patients in the matched control group was approximately 100% compared with their initial ICU hospitalization state vs 0% percent worsening in the organ-failure state of AllocetraTM-treated patients after treatment (p<0.0001). The ICU length-of-stay for all AllocetraTM-treated patients was significantly shorter than those patients who received only the standard of care, with an average of 4.7 days compared to 11.1 days in the matched controls group, a 58% reduction (p<0.0001). The slowest ICU discharge of a patient treated with AllocetraTM was after 8 days, while approximately 50% of the matched controls group remained in the ICU after 21 days.
Another 100% survival rate.
This really seems to be a miracle drug for these diseases.
Positions: March 2021 $25 calls, May 2021 $25 calls, and shares
Not investment advice. Not a financial advisor.
News 
Market Data 
Discover 
